Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients

“…However, the difference between the intermediate and poor prognostic groups was not statistically significant [16].…”

“…Elevated ALP was significantly related to worse survival in univariate analyses [16]. Prognostic factors from the GETUG-15 trial were used to define three prognostic subgroups of survival in hormone-naïve prostate cancer.…”

1009 Serum lactate dehydrogenase and survival following cancer diagnosis

“…Similar associations with survival have been established in chronic myeloid and lymphocytic leukaemias (Weinberg et al, 2007;Goldaniga et al, 2008) and small cell lung cancer (SCLC) (You et al, 2008;Danner et al, 2010). In recent clinical trials, elevated serum LDH has been shown as an independent predictor of overall survival in advanced or metastatic cancer of the breast (Brown et al, 2012), prostate (Scher et al, 2009;Gravis et al, 2014), colorectum (Bar et al, 2014), oesophagus (Polee et al, 2003), pancreas (Tas et al, 2001), ovary (Schneider et al, 1998), nasopharynx (Jin et al, 2013), gastric adenocarcinoma (Sougioultzis et al, 2011), hepatocellular carcinoma (HCC) (Faloppi et al, 2014), renal cell carcinoma (Armstrong et al, 2012) and melanoma (Balch et al, 2004;Weide et al, 2012). The inverse association with overall survival in solid tumours were shown in a recent meta-analysis, with HR for overall death of 1.7 (95% CI: 1.62-1.79) (Petrelli et al, 2015).…”

Current treatment strategies for advanced prostate cancer

“…51 A number of factors potentially predicting the treatment outcome, such as serum lactate dehydrogenase 32,52 and alkaline phosphatase, 53 have been recognized as potential markers for the treatment of APC. In addition, a number of studies including post-hoc analysis have further provided new insights for a higher NLR predicting lower response rate to abiraterone, 54 and a higher dNLR (dNLR = absolute neutrophil count / white blood cells -absolute neutrophil count) predicting shorter OS to docetaxel 55 (post-hoc analysis from VENICE and TAX327 studies), whereas cabazitaxel had a comparable effect on OS in patients with a higher NLR in a post-hoc analysis from TROPIC study.…”